CompletedPhase 2NCT02280616

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

Studying NON RARE IN EUROPE: Eosinophilic esophagitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dr. Falk Pharma GmbH
Principal Investigator
Ralph Mueller, PhD
Dr. Falk Pharma GmbH
Intervention
low dose budesonide tablet(drug)
Enrollment
76 enrolled
Eligibility
18-75 years · All sexes
Timeline
20112014

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02280616 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Eosinophilic esophagitis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Eosinophilic esophagitis

← Back to all trials